Astera Labs, Inc.
Astera Labs (ALAB) reported record Q2 2026 revenue of $392.4M, up 104% year over year, with PCIe 6 products at over 50% of revenue. The company said Scorpio X-Series will be its largest product family by Q3 2026. It expects Q3 revenue of $540M-$560M. The article also cites competition from Marvell (MRVL) and Credo (CRDO).
Astera Labs (NASDAQ:ALAB) reported Q2 2026 revenue of $392.4M, up 27% sequentially and 104% year over year, with non-GAAP gross margin of 73.7% and non-GAAP diluted EPS of $0.80. Q3 guidance calls for revenue of $540M to $560M and EPS of $1.16 to $1.21, driven by the Scorpio X-Series ramp and PCIe 6.0 adoption.
Alamar Biosciences shares rose about 18% after the company reported Q2 2026 revenue of $29.4 million, up 82% year over year, and provided first full-year 2026 revenue guidance of $116 million to $120 million. The stock closed at $32.91. Alamar also launched new NULISAseq panels and set targets to exceed 100 instrument systems and $400,000+ annual pull-through per instrument.
Over the past 7 days, alphai's AI scored 4 news stories mentioning ALAB (Astera Labs, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent ALAB coverage spans earnings, insider activity and technology.
In the last 30 days, ALAB insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($3.9M). The most active reporter was Dyckerhoff Stefan A with 9 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Strong PCIe 6-led growth plus Q3 revenue guidance ($540M-$560M) tied to Scorpio and Aries supports a bullish near-term setup.
Guidance and margin expansion tied to PCIe 6.0 and Scorpio X-Series ramps suggest near-term upside if execution matches, but gross margin may normalize as mix shifts.
The print and inaugural full-year revenue guide are likely to drive continued momentum and repricing versus IPO-era expectations.
This is a routine insider sale under a pre-arranged 10b5-1 plan, so it is more of a sentiment signal than a fundamental catalyst.
A routine 10b5-1 insider sale provides limited signal, but it can still affect near-term sentiment and positioning.
alphai scores every news story that mentions ALAB with an AI model for sentiment and relevance, and aggregates insider trades from Astera Labs, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Astera Labs (ALAB) reported record Q2 2026 revenue of $392.4M, up 104% year over year, with PCIe 6 products at over 50% of revenue. The company said Scorpio X-Series will be its largest product family by Q3 2026. It expects Q3 revenue of $540M-$560M. The article also cites competition from Marvell (MRVL) and Credo (CRDO).
6 min readAstera Labs (NASDAQ:ALAB) reported Q2 2026 revenue of $392.4M, up 27% sequentially and 104% year over year, with non-GAAP gross margin of 73.7% and non-GAAP diluted EPS of $0.80. Q3 guidance calls for revenue of $540M to $560M and EPS of $1.16 to $1.21, driven by the Scorpio X-Series ramp and PCIe 6.0 adoption.
6 min readAlamar Biosciences shares rose about 18% after the company reported Q2 2026 revenue of $29.4 million, up 82% year over year, and provided first full-year 2026 revenue guidance of $116 million to $120 million. The stock closed at $32.91. Alamar also launched new NULISAseq panels and set targets to exceed 100 instrument systems and $400,000+ annual pull-through per instrument.
6 min readDyckerhoff Stefan A sold 8,994 indirectly-held shares of Astera Labs, Inc. (ALAB) at an average of $311.83 ($309.29–$313.07, $2.80M total) across 6 trades on 2026-08-06 under a Rule 10b5-1 trading plan.
2 min readDyckerhoff Stefan A sold 3,505 shares of Astera Labs, Inc. (ALAB) at an average of $311.83 ($309.29–$313.07, $1.09M total) across 3 trades on 2026-08-06 under a Rule 10b5-1 trading plan.
2 min readAstera Labs (ALAB) reported Q2 2026 revenue of $392.4M and net income of $153.09M, versus higher year-ago figures, and six-month revenue of $700.76M and net income of $233.4M. For Q3 2026, it guided revenue of $540M to $560M and GAAP diluted EPS of $0.87 to $0.92.
5 min readSimply Wall St reports Astera Labs (ALAB) posted record Q2 2026 revenue and earnings, with higher operating expenses tied to product investments. The stock closed at $334.17, up 7.37% over 7 days and 67.26% over 90 days. A fair value estimate of $244.97 suggests it is overvalued, with risks including AI capex slowdowns and competing interconnect integration.
6 min readAstera Labs (ALAB) reported record fiscal Q2 2026 results, with revenue of $392.4M up 104% year over year, and issued fiscal Q3 2026 guidance of $540M to $560M, above expectations. The stock later fell about 12% after four prior up sessions. The article attributes the shift to product mix, with PCIe 6 and Scorpio switch family ramping, and a non-GAAP gross margin guide down to about 72% from 74%.
6 min readAstera Labs (ALAB) shares fell about 12% to around $318 after its Q2 earnings. The company reported adjusted EPS of $0.80 on revenue of $392.4 million, and Q3 guidance of $540 million to $560 million revenue and non-GAAP EPS of $1.16 to $1.21. Analysts cited high expectations tied to the Scorpio ramp; valuation models estimate a ~$320 target by 2028.
6 min readAstera Labs (ALAB) shares fell 12% after its Aug. 4, 2026 Q2 results, as higher operating expenses reflected continued investment in its product roadmap, amid macro uncertainty and competition. The stock is up 91.4% YTD on strong AI connectivity demand. For Q3 2026, revenue guidance is $540M-$560M and non-GAAP EPS $1.16-$1.21.
6 min read
